Any current/future new fundraising through debt or equity?

The transcript of Divi's Laboratories Limited's earnings call dated May 23, 2026, does not mention any current or planned fundraising through debt or equity. No explicit references to new debt issuance or equity fundraising were discussed during the call. The company highlighted significant ongoing capital expenditure (Capex) of ₹2,500 crores for the year and a capital work in progress of ₹2,113 crores as of March 31, 2026. Cash and cash equivalents as of March 31, 2026, stood at ₹3,414 crores, indicating strong liquidity. The management did not disclose any plans for raising funds through deb

Any current/future capex/capital investment/strategic investment?

Capital work in progress as of March 31, 2026, stood at approximately ₹2,113 crores. Significant capex of ₹1,544 crores was capitalized during the financial year 2025-26, with around ₹800 crores capitalized in the last quarter. Ongoing ₹1,500 crores expansion plan at Kakinada, of which ₹600 crores has been capitalized. Expected capex for the next fiscal year (FY27) to be fairly constant, barring any major new or custom synthesis projects. Capex allocated towards creating GMP capacities across multiple units, including freeing up spaces and qualifying raw materials. Timeline for commercializati

Future growth expectations in sales/revenue/volumes?

The company aims for **double-digit revenue growth** moving forward, as stated by Nilima Prasad Divi. Growth is expected both from **existing generic product volumes** and **new product additions** in the pipeline. Custom synthesis projects under development are seen as **potential contributors to future revenue**, though their timelines are uncertain (ranging from 6 months to 3 years). Volume growth is anticipated not only from the **current product portfolio** but also from **new molecules launching in the coming years**. Despite pricing pressures, steady and **healthy volume increases in th

Future growth expectations in earnings/operating earnings/profits/EPS?

Divi's Laboratories aims for double-digit revenue growth, as stated by Nilima Prasad Divi on the call. Profit margins are expected to remain stable in the near term amid cost pressures and currency fluctuations. Capex of ₹2,500 crores (24% of sales) indicates significant investment, but revenue recognition from these projects may take 1-3 years, depending on regulatory approvals and customer timelines. Management expressed caution on margin expansion due to uncertainties in product market performance and continued generic pricing pressures. Long-term supply agreements provide revenue visibilit

Current/ Expected Orderbook/ Pending Orders?

Divi's Laboratories does not disclose specific volumes, pricing, or costing of long-term supply agreements as the technology is customer-owned and confidential. The company mentioned ongoing efforts to minimize the impact of rising raw material costs by discussing and stabilizing terms with customers. Regarding dedicated capex projects, the management is unable to comment on upside or downside impact on stable profitability guidance due to uncertainties in customer order timing. The three dedicated custom synthesis (CS) capacity projects have passed various validation stages and are in the pro

IN US

Sale is live|00:00:00left today

Divis Laboratories LtdQ1 FY26Pharmaceuticals & Biotechnology

Divis Laboratories Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6,768P/E: 70.3Market Cap: ₹1.8L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company aims for **double-digit revenue growth** moving forward, as stated by Nilima Prasad Divi.
→Growth is expected both from **existing generic product volumes** and **new product additions** in the pipeline.
→Custom synthesis projects under development are seen as **potential contributors to future revenue**, though their timelines are uncertain (ranging from 6 months to 3 years).
→Volume growth is anticipated not only from the **current product portfolio** but also from **new molecules launching in the coming years**.
→Despite pricing pressures, steady and **healthy volume increases in the API segment** have been observed recently.
→The company continues to invest significantly in capacity expansion (₹2,500 crores capex this year), positioning for scaling up future sales.
→Revenue recognition from new capex projects depends on customer timelines and regulatory approvals, making exact forecasts challenging.

Margin guidance

Category 3

→Divi's Laboratories aims for double-digit revenue growth, as stated by Nilima Prasad Divi on the call.
→Profit margins are expected to remain stable in the near term amid cost pressures and currency fluctuations.
→Capex of ₹2,500 crores (24% of sales) indicates significant investment, but revenue recognition from these projects may take 1-3 years, depending on regulatory approvals and customer timelines.
→Management expressed caution on margin expansion due to uncertainties in product market performance and continued generic pricing pressures.
→Long-term supply agreements provide revenue visibility but limit commentary on volume/pricing upside.
→Currency depreciation benefits exports but may also cause impact when rupee fluctuates.
→Overall, management expects steady profit growth aligned with revenue, with cautious optimism on margin stability rather than expansion in the short term.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript of Divi's Laboratories Limited's earnings call dated May 23, 2026, does not mention any current or planned fundraising through debt or equity.
→No explicit references to new debt issuance or equity fundraising were discussed during the call.
→The company highlighted significant ongoing capital expenditure (Capex) of ₹2,500 crores for the year and a capital work in progress of ₹2,113 crores as of March 31, 2026.
→Cash and cash equivalents as of March 31, 2026, stood at ₹3,414 crores, indicating strong liquidity.
→The management did not disclose any plans for raising funds through debt or equity in the near future during the call.

Order book

→Divi's Laboratories does not disclose specific volumes, pricing, or costing of long-term supply agreements as the technology is customer-owned and confidential.
→The company mentioned ongoing efforts to minimize the impact of rising raw material costs by discussing and stabilizing terms with customers.
→Regarding dedicated capex projects, the management is unable to comment on upside or downside impact on stable profitability guidance due to uncertainties in customer order timing.
→The three dedicated custom synthesis (CS) capacity projects have passed various validation stages and are in the process of supply to customers, with commercial production starting upon customer regulatory approvals and volume confirmation.
→The timeline for ramp-up depends on customer approvals and regulatory filings, which Divi’s does not control or comment on.
→Orderbook specifics and pending order quantities are not publicly shared due to confidentiality and the nature of customer-owned technology.

Capex plans

Yes

→Capital work in progress as of March 31, 2026, stood at approximately ₹2,113 crores.
→Significant capex of ₹1,544 crores was capitalized during the financial year 2025-26, with around ₹800 crores capitalized in the last quarter.
→Ongoing ₹1,500 crores expansion plan at Kakinada, of which ₹600 crores has been capitalized.
→Expected capex for the next fiscal year (FY27) to be fairly constant, barring any major new or custom synthesis projects.
→Capex allocated towards creating GMP capacities across multiple units, including freeing up spaces and qualifying raw materials.
→Timeline for commercialization of some dedicated contract manufacturing projects expected around 2027, subject to regulatory approvals.
→Future capex plans may be updated publicly as and when material developments occur.

How does Divis Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Divis Laboratories Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Divis Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio